Clinical Prediction Models for Recurrence in Patients with Resectable Grade 1 and 2 Sporadic Non-Functional Pancreatic Neuroendocrine Tumors: A Systematic Review.
Jeffrey W ChenCharlotte M HeidsmaAnton F EngelsmanErtunç KabaktepeSusan van DierenMassimo FalconiMarc G BesselinkEls J M Nieveen van DijkumPublished in: Cancers (2023)
Recurrence after resection in patients with non-functional pancreatic neuroendocrine tumors (NF-pNET) has a considerable impact on overall survival. Accurate risk stratification will tailor optimal follow-up strategies. This systematic review assessed available prediction models, including their quality. This systematic review followed PRISMA and CHARMS guidelines. PubMed, Embase, and the Cochrane Library were searched up to December 2022 for studies that developed, updated, or validated prediction models for recurrence in resectable grade 1 or 2 NF-pNET. Studies were critically appraised. After screening 1883 studies, 14 studies with 3583 patients were included: 13 original prediction models and 1 prediction model validation. Four models were developed for preoperative and nine for postoperative use. Six models were presented as scoring systems, five as nomograms, and two as staging systems. The c statistic ranged from 0.67 to 0.94. The most frequently included predictors were tumor grade, tumor size, and lymph node positivity. Critical appraisal deemed all development studies as having a high risk of bias and the validation study as having a low risk of bias. This systematic review identified 13 prediction models for recurrence in resectable NF-pNET with external validations for 3 of them. External validation of prediction models improves their reliability and stimulates use in daily practice.
Keyphrases
- systematic review
- lymph node
- neuroendocrine tumors
- signaling pathway
- case control
- healthcare
- end stage renal disease
- primary care
- oxidative stress
- lps induced
- ejection fraction
- chronic kidney disease
- nuclear factor
- free survival
- physical activity
- toll like receptor
- randomized controlled trial
- newly diagnosed
- neoadjuvant chemotherapy
- cell proliferation
- quality improvement
- prognostic factors
- mass spectrometry
- late onset
- peritoneal dialysis
- clinical practice
- rectal cancer